...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells
【24h】

Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells

机译:前列腺癌细胞中溶血磷脂酸受体1,游离脂肪酸受体4和表皮生长因子受体之间的正负交叉对话

获取原文
获取原文并翻译 | 示例

摘要

Lysophosphatidic acid (LPA) is a lipid mediator that mediates cellular effects via G protein-coupled receptors (GPCRs). Epidermal growth factor (EGF) is a peptide that acts via a receptor tyrosine kinase. LPA and EGF both induce proliferation of prostate cancer cells and can transactivate each other's receptors. The LPA receptor LPA(1) is particularly important for LPA response in human prostate cancer cells. Previous work in our laboratory has demonstrated that free fatty acid 4 (FFA4), a GPCR activated by omega-3 fatty acids, inhibits responses to both LPA and EGF in these cells. One potential mechanism for the inhibition involves negative interactions between FFA4 and LPA(1), thereby suppressing responses to EGF that require LPA(1). In the current study, we examined the role of LPA(1) in mediating EGF and FFA4 agonist responses in two human prostate cancer cell lines, DU145 and PC-3. The results show that an LPA(1)-selective antagonist inhibits proliferation and migration to both LPA and EGF. Knockdown of LPA(1) expression, using silencing RNA, blocks responses to LPA and significantly inhibits responses to EGF. The partial response to EGF that is observed after LPA(1) knockdown is not inhibited by FFA4 agonists. Finally, the role of arrestin-3, a GPCR-binding protein that mediates many actions of activated GPCRs, was tested. Knockdown of arrestin-3 completely inhibits responses to both LPA and EGF in prostate cancer cells. Taken together, these results suggest that LPA(1) plays a critical role in EGF responses and that FFA4 agonists inhibit proliferation by suppressing positive cross-talk between LPA(1) and the EGF receptor.
机译:溶血磷脂酸(LPA)是一种脂质介体,可通过G蛋白偶联受体(GPCR)介导细胞作用。表皮生长因子(EGF)是一种通过受体酪氨酸激酶起作用的肽。 LPA和EGF都可以诱导前列腺癌细胞的增殖,并且可以使彼此的受体激活。 LPA受体LPA(1)对于人前列腺癌细胞中的LPA反应特别重要。我们实验室以前的工作表明,游离脂肪酸4(FFA4)是一种由omega-3脂肪酸激活的GPCR,可抑制这些细胞对LPA和EGF的反应。一种潜在的抑制机制涉及FFA4和LPA(1)之间的负性相互作用,从而抑制对需要LPA(1)的EGF的反应。在当前的研究中,我们检查了LPA(1)在两种人前列腺癌细胞系DU145和PC-3中介导EGF和FFA4激动剂反应中的作用。结果表明,LPA(1)选择性拮抗剂抑制增殖和迁移到LPA和EGF。使用沉默RNA抑制LPA(1)表达,可阻断对LPA的反应并显着抑制对EGF的反应。 LFA(1)敲低后观察到的对EGF的部分反应不受FFA4激动剂的抑制。最后,测试了抑制蛋白3(一种介导激活的GPCR的许多作用的GPCR结合蛋白)的作用。抑制restin-3完全抑制前列腺癌细胞对LPA和EGF的反应。综上所述,这些结果表明LPA(1)在EGF反应中起关键作用,而FFA4激动剂通过抑制LPA(1)与EGF受体之间的正向相互作用来抑制增殖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号